|
1
|
Eltabbakh G and Awtrey C: Current
treatment for ovarian cancer. Expert Opin Pharmacother. 2:109–124.
2001. View Article : Google Scholar
|
|
2
|
McKeage M: New-generation platinum drugs
in the treatment of cisplatin-resistant cancers. Expert Opin
Investig Drugs. 14:1033–1046. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tewari K, Mehta R, Burger R, et al:
Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs.
10:413–442. 2005. View Article : Google Scholar
|
|
4
|
Chen H, Hardy TM and Tollefsbol TO:
Epigenomics of ovarian cancer and its chemoprevention. Front Genet.
2:672011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee S, Choi E, Jin C, et al: Activation of
PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification
contributes to cisplatin resistance in an ovarian cancer cell line.
Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrandina G, Legge F, Martinelli E, et
al: Survivin expression in ovarian cancer and its correlation with
clinico-pathological, surgical and apoptosis-related parameters. Br
J Cancer. 92:271–277. 2005.
|
|
7
|
Liguang Z, Peishu L, Hongluan M, et al:
Survivin expression in ovarian cancer. Exp Oncol. 29:121–125.
2007.PubMed/NCBI
|
|
8
|
No JH, Jeon YT, Kim YB, et al:
Quantitative detection of serum survivin and its relationship with
prognostic factors in ovarian cancer. Gynecol Obstet Invest.
71:136–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qian X, Xi X and Li L: Nuclear survivin is
associated with malignant potential in epithelial ovarian
carcinoma. Appl Immunohistochem Mol Morphol. 19:126–132. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kleinberg L, Flørenes VA, Silins I, et al:
Nuclear expression of survivin is associated with improved survival
in metastatic ovarian carcinoma. Cancer. 109:228–238. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zaffaroni N, Pennati M, Colella G, et al:
Expression of the anti-apoptotic gene survivin correlates with
taxol resistance in human ovarian cancer. Cell Mol Life Sci.
59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Felisiak-Golabek A, Rembiszewska A,
Rzepecka IK, et al: Nuclear survivin expression is a positive
prognostic factor in taxane-platinum-treated ovarian cancer
patients. J Ovarian Res. 4:202011. View Article : Google Scholar
|
|
13
|
Ma X, Wang S, Zhou J, et al: Induction of
apoptosis in human ovarian epithelial cancer cells by antisurvivin
oligonucleotides. Oncol Rep. 14:275–279. 2005.PubMed/NCBI
|
|
14
|
Caldas H, Jaynes FO, Boyer MW, et al:
Survivin and Granzyme B-induced apoptosis, a novel anticancer
therapy. Mol Cancer Ther. 5:693–703. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang B, Pan JS, Liu JY, et al: Effects of
chemotherapy and/or radiotherapy on survivin expression in ovarian
cancer. Methods Find Exp Clin Pharmacol. 28:619–625. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Liao H, Chen X, et al:
Luteinizing hormone upregulates survivin and inhibits apoptosis in
ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol.
155:69–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang Y, Jin H, Liu Y, et al: FSH inhibits
ovarian cancer cell apoptosis by up-regulating survivin and
down-regulating PDCD6 and DR5. Endocr Relat Cancer. 18:13–26. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tu CH, Liu WP, Dong M, et al: Protection
of CHO cells by transfer of survivin driven by ovarian-specific
promoter OSP-2. Mol Biol Rep. 38:2323–2328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roca H, Craig MJ, Ying C, et al: IL-4
induces proliferation in prostate cancer PC3 cells under
nutrient-depletion stress through the activation of the JNK-pathway
and survivin up-regulation. J Cell Biochem. 113:1569–1580.
2012.PubMed/NCBI
|
|
20
|
Xing J, Jia CR, Wang Y, et al: Effect of
shRNA targeting survivin on ovarian cancer. J Cancer Res Clin
Oncol. 138:1221–1229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakahara T, Kita A, Yamanaka K, et al:
Broad spectrum and potent antitumor activities of YM155, a novel
small-molecule survivin suppressant, in a wide variety of human
cancer cell lines and xenograft models. Cancer Sci. 102:614–621.
2011. View Article : Google Scholar
|
|
22
|
Zheng F, Ruan F, Xie XK, et al: Apoptosis
of drug-resistant human ovarian carcinoma cell line COC1/DDP
induced by survivin antisense oligonucleotides. Chin Med J (Engl).
119:1572–1575. 2006.PubMed/NCBI
|
|
23
|
Zhang HY, Zhang PN and Sun H: Aberration
of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its
implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol
Reprod Biol. 146:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weng D, Song X, Xing H, et al: Implication
of the Akt2/survivin pathway as a critical target in paclitaxel
treatment in human ovarian cancer cells. Cancer Lett. 273:257–265.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xing H, Weng D, Chen G, et al: Activation
of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by
regulating survivin protein expression in ovarian and breast cancer
cells. Cancer Lett. 261:108–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Raj MH, Abd Elmageed ZY, Zhou J, et al:
Synergistic action of dietary phyto-antioxidants on survival and
proliferation of ovarian cancer cells. Gynecol Oncol. 110:432–438.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Azrak RG, Frank CL, Ghadersohi A, et al:
Silencing survivin results in synergy between methylseleninic acid
and paclitaxel against skov3 ovarian cancer cells. Cancer Biol
Ther. 7:1901–1908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vivas-Mejia PE, Rodriguez-Aguayo C, Han
HD, et al: Silencing survivin splice variant 2B leads to antitumor
activity in taxane - resistant ovarian cancer. Clin Cancer Res.
17:3716–3726. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reitmaier M, Rudlowski C, Biesterfeld S,
et al: Comparative studies on the biological significance of the
marker for proliferation Ki-67-antigen and PCNA in primary ovarian
carcinoma. Zentralbl Gynakol. 122:361–367. 2000.(In German).
|
|
30
|
Brinckerhoff CE, Rutter JL and Benbow U:
Interstitial collagenases as markers of tumor progression. Clin
Cancer Res. 6:4823–4830. 2000.PubMed/NCBI
|
|
31
|
Flick MB, O’Malley D, Rutherford T, et al:
Apoptosis-based evaluation of chemosensitivity in ovarian cancer
patients. J Soc Gynecol Investig. 11:252–259. 2004. View Article : Google Scholar : PubMed/NCBI
|
